share_log

沃森生物(300142.SZ):在研的mRNA疫苗产品主要以预防传染性疾病为主

Walvax Biotechnology (300142.SZ): The mRNA vaccine products under development primarily focus on preventing infectious diseases.

Gelonghui Finance ·  Dec 26, 2024 03:06

On December 26th, Gelonghui reported that Walvax Biotechnology (300142.SZ) recently stated during an investor relations activity that the current main research areas of mRNA vaccine development are infectious diseases and cancer, and that it is beginning to explore the shift from preventive products to therapeutic products. Since its establishment, the company has remained focused on the research and production of innovative blockbuster vaccines, with its mRNA vaccine products primarily aimed at preventing infectious diseases. The company will closely monitor the application of new technologies in innovative fields like cancer and the development of related products.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment